Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Area of Science:

• Oncology
• Immunotherapy
• Cancer Biology

Background:

• Mesothelin is a tumor antigen highly expressed in cancers like mesothelioma, pancreatic, ovarian, and lung adenocarcinomas.
• Its restricted normal expression makes it an attractive target for cancer immunotherapy.
• Mesothelin-targeted therapies are being developed due to the dispensable nature of normal mesothelial cells.

Purpose of the Study:

• To review the current landscape of mesothelin-targeted immunotherapies.
• To highlight ongoing clinical evaluations of novel therapeutic agents.
• To assess the potential utility of mesothelin-based treatments in human cancers.

Main Methods:

• Review of clinical trial data and therapeutic agent development.
• Inclusion of antibody-based therapies, vaccines, and T-cell therapies.
• Focus on agents in clinical evaluation for malignant mesothelioma and pancreatic cancer.

Main Results:

• Multiple antimesothelin agents are in clinical trials, including immunotoxins, antibody-drug conjugates, and cellular therapies.
• Amatuximab and anetumab ravtansine are in registration trials for malignant mesothelioma.
• CRS-207 is being evaluated in combination with immune checkpoint inhibitors for pancreatic cancer.

Conclusions:

• Mesothelin immunotherapy represents a promising approach for treating various human cancers.
• Ongoing clinical trials are crucial for determining the efficacy and role of these therapies.
• Further research will define the clinical utility of targeting mesothelin in cancer treatment.